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Abstract
Background: The additional clinical value of clustering cardiovascular risk factors to define the metabolic syndrome (MetS)
is still under debate. However, it is unclear which cardiovascular risk factors tend to cluster predominately and how
individual risk factor states change over time.
Methods & Results: We used data from 3,187 individuals aged 20–79 years from the population-based Study of Health in
Pomerania for a network-based approach to visualize clustered MetS risk factor states and their change over a five-year
follow-up period. MetS was defined by harmonized Adult Treatment Panel III criteria, and each individual’s risk factor
burden was classified according to the five MetS components at baseline and follow-up. We used the map generator to
depict 32 (2
5) different states and highlight the most important transitions between the 1,024 (32
2) possible states in the
weighted directed network. At baseline, we found the largest fraction (19.3%) of all individuals free of any MetS risk factors
and identified hypertension (15.4%) and central obesity (6.3%), as well as their combination (19.0%), as the most common
MetS risk factors. Analyzing risk factor flow over the five-year follow-up, we found that most individuals remained in their
risk factor state and that low high-density lipoprotein cholesterol (HDL) (6.3%) was the most prominent additional risk factor
beyond hypertension and central obesity. Also among individuals without any MetS risk factor at baseline, low HDL (3.5%),
hypertension (2.1%), and central obesity (1.6%) were the first risk factors to manifest during follow-up.
Conclusions: We identified hypertension and central obesity as the predominant MetS risk factor cluster and low HDL
concentrations as the most prominent new onset risk factor.
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Introduction
The metabolic syndrome (MetS) has gained recent attention as
a multifactorial cluster of cardiovascular risk factors linked to
criteria of adiposity, hypertension, dyslipidemia, and hyperglycae-
mia. Although associations between MetS and incident cardiovas-
cular disease (CVD) have been repeatedly observed [1], there is an
ongoing controversy about its clinical value and impact [2–6].
Compared to established CVD risk scores, MetS is a relatively
weak predictor of incident CVD and its single components showed
a comparable or even better predictive utility, respectively [7–9].
We previously showed that there was no added predictive value of
MetS beyond its individual components with respect to mortality
risk [10] and concluded in line with others to redirected attention
to its individual components, particularly central obesity and
hyperglycaemia [10,11]. Also with regard to cardiovascular risk,
MetS was admittedly associated with accelerated central arterial
ageing, but specific clusters of MetS components showed
dramatically increased arterial changes [12]. But although these
outcome associations may give a clue which risk factors drive the
underlying MetS pathophysiology, investigations which MetS
components tend to cluster predominately and how individual risk
factor states change over time are scarce [13,14]. Therefore, we
used a novel network-based approach to visualize clustered MetS
components and their change during a five-year follow-up period
among 3,187 participants from the population-based Study of
Health in Pomerania (SHIP).
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Ethics statement
The study protocol was consistent with the principles of the
Declaration of Helsinki and approved by the local Ethics
Committee of the University of Greifswald.
Study population
The SHIP is a population-based cohort study conducted in
Northeast Germany. Details about the study’s sampling method,
design, and exams were published previously [15]. A representa-
tive sample comprising of 7,008 individuals was selected using
population registries where all German inhabitants are registered.
Only individuals with German citizenship and main residency in
the study area were included. The net sample (without migrated or
deceased persons) comprised 6,267 eligible individuals. At
baseline, SHIP finally comprised 4,308 (2,116 men) participants
(response 68.8%) with examinations conducted between 1997 and
2001. Between 2002 and 2006, all participants were re-invited to
a five-year follow-up examination, and 3,300 individuals (1,589
men) participated (response 83.5%). All participants gave written
informed consent. Of the 3,300 individuals attending SHIP
baseline and follow-up examinations we excluded individuals with
missing data on MetS components, analyzing a final study
population of 3,187 individuals (1,546 men).
Measures
Baseline and follow-up examinations included a computer-
assisted personal interview, as well as somatometric, medical, and
laboratory measurements. Waist circumference (WC) was mea-
sured to the nearest 0.1 cm using an inelastic tape midway
between the lower rib margin and the iliac crest in the horizontal
plane, with the subject standing comfortably with weight
distributed evenly on both feet. After a resting period of at least
five minutes, systolic and diastolic blood pressure was measured
three times in the right arm of seated participants using a digital
blood pressure monitor (HEM-705CP, Omron Corporation,
Tokyo, Japan) with each reading being followed by a three-minute
pause. The second and third readings were averaged to give the
mean diastolic and systolic blood pressure.
Non-fasting blood samples were taken from the cubital vein in
the supine position between 7:00 a.m. and 7:00 p.m. and prepared
for immediate analysis or for storage at 280uC for further analysis.
Serum high-density lipoprotein (HDL) cholesterol concentrations
were measured photometrically at baseline (Hitachi 704, Roche,
Mannheim, Germany), whereas follow-up HDL concentrations
were quantified by lipid electrophoresis (HELENA SAS-3 system,
Helena 7 BioSciences Europe, Tyne & Wear, UK). To ensure
comparability in the longitudinal HDL analyses, we used baseline
HDL concentrations as the reference and calculated corrected
follow-up HDL concentrations based on a previously published
conversion formula [16]. Doing so, we found that the average
HDL concentrations produced by the two methods were virtually
identical, suggesting that the differences in HDL will be small
within the range of practical relevance [17]. Serum triglyceride
and glucose concentrations were determined enzymatically using
reagents from Roche Diagnostics (Hitachi 717, Roche Diagnostics,
Mannheim, Germany). All assays were performed according to the
manufacturers’ recommendations by skilled technical personnel,
and internal quality controls were analyzed daily. In addition, the
laboratory participates in official quarterly German external
proficiency testing programs. Type 2 diabetes mellitus was defined
based on self-reported physicians diagnosis or use of antidiabetic
medication (anatomic-therapeutical-chemical [ATC] code A10) in
the last seven days, or glycated haemoglobin (HbA1c) concentra-
tions .48.0 mmol/mol. CVD was defined one or more
components of a previously published summative score comprising
information about peripheral artery disease, heart failure, angina
pectoris, and a recall of physician’s diagnoses of stroke and
myocardial infarction [18].
Diagnostic criteria for the assessment of MetS components were
defined according the Joint Scientific Statement to harmonize
MetS [19] and modified for the use of non-fasting blood samples,
as previously established in SHIP [20,21] and other large cohorts
[22,23]:
1. elevated WC: men .94 cm, women .80 cm;
2. elevated non-fasting glucose: $8.0 mmol/l or antidiabetic
treatment (ATC code A10A);
3. decreased HDL cholesterol: men ,1.0 mmol/l, women
,1.3 mmol/l, or lipid-lowering treatment (ATC C10AB,
A10AD);
4. elevated non-fasting triglycerides: $2.3 mmol/l or lipid-
lowering treatment (ATC C10AB, A10AD);
5. elevated blood pressure: $130/85 mmHg or antihypertensive
drug treatment (ATC codes C02, C03, C04, C07, C08, C09).
Participants fulfilling at least three out of these five components
were assigned to MetS.
Statistical Analysis
Categorical data are reported as percentages, and continuous
data are reported as median together with the interquartile range.
The individual risk factor burden was classified to states according
to the five MetS components at baseline and follow-up. With five
MetS components, there are 2
5=32 different states and
32
2=1,024 possible transitions between states from baseline to
follow-up. We represented this data as a weighted directed
network with states as nodes and transitions between states as
weighted directed links between the nodes. We used the map
generator at http://www.mapequation.org/mapgenerator/ to
generate a map of risk factor flow between the potential risk
factor states, including the state ‘‘healthy’’ with absence of any
MetS risk factors. Figure 1 shows the risk factor map with link
width and intensity proportional to the weight of the links and
node size proportional to the number of individuals assigned to it
at baseline. The inner circle of a node represents the number of
individuals that remain in that state between baseline and follow-
up (self-links), and the outer ring represents the number of
individuals that transits to a different risk factor state. To evaluate
potential non-response bias due to drop out between baseline and
the five-year follow-up examination, baseline characteristics of
follow-up responder vs. non-responder were compared using x
2
tests for categorical data or two-sample t-tests for continuous data.
As expected, we observed that follow-up non-responder were on
average older, male, and exposed adverse cardiometabolic risk
factor profiles compared to follow-up responder, but found no
differences in MetS prevalence, the main outcome of the present
study. Data preparation and descriptive statistics were performed
with Stata 11.0 (Stata Corp., College Station, TX, USA).
Results
Characteristics of the study population at baseline and follow-up
are presented in Table 1. MetS prevalence at baseline was 27.6%
and 42.4% after a median follow-up time of 5.0 years, re-
spectively. The risk factor network in Figure 1 shows the baseline
risk factor profiles of 3,187 individuals and how their profiles
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depicted network only shows the 28 most prevalent profiles,
representing 91% of all possible risk factor states at baseline. For
the same reason, we have only included the 39 strongest
connections (13% of links), but nevertheless captured 85% of all
risk factor flow. At baseline, we found the largest fraction (19.3%
of all individuals) in the healthy state without any MetS risk
factors, of which 58% remained risk factor free and 42%
developed risk factors at follow-up (11.1% of all individuals were
without any MetS risk factors at baseline and follow-up) (Table 2).
We identified hypertension (15.4% ‘‘BP’’) and central obesity
(6.3% ‘‘Obesity’’), as well as their combination (19.0%) as the most
common MetS risk factors. In Table 2 we present detailed
information about the most common risk factor states that each
comprised more than 5% of the overall sample. The largest risk
factor flow in terms of number of individuals was the transition
from hypertension and central obesity to additional low HDL
concentrations at follow-up (6.3%). The largest risk factor flows
from the healthy state were to low HDL concentrations (3.5%),
hypertension (2.1%), and central obesity (1.6%) (Table 3). But in
general, most individuals remained in their risk factor state, and
self-links dominated the risk factor flow network during the five-
year follow-up (Table 3).
Discussion
The present network-based analyses of longitudinal data from
3,187 individuals identified hypertension and central obesity as the
most common MetS components. These MetS components also
constituted the predominant risk factor cluster during follow-up.
Analyzing risk factor change, we revealed low HDL concentra-
tions as the most common additional and new onset MetS
component. This is the first network-based approach to pre-
dictively model cardiovascular risk factor burden and expression.
To better understand which MetS components tend to cluster
predominately and how individual risk factor states change over
time, we not only explored the topology of the MetS risk factor
network, but also its dynamic changes over a five-year follow-up
period.
Although the MetS network contains a plethora of potentially
interconnected cardiovascular risk factor states, only some are
truly relevant to the pathophenotype MetS and its suggested
outcome associations with CVD and mortality [12,24–27]. The
commonly as most relevant MetS components considered
cardiovascular risk factors are central obesity and insulin re-
sistance. But although insulin resistance is the hallmark of MetS,
central obesity is the most relevant predisposing factor for insulin
resistance [28]. Thus, the finding of a predominant role of central
obesity, but not glycaemia, in our MetS network is likely explained
Figure 1. Metabolic syndrome network visualizing cardiovascular risk factor burden, clustering, and flow of its components
between baseline and five-year follow-up. ‘‘Healthy’’, no prevalent metabolic syndrome component; ‘‘Obesity’’, waist circumference: men
.94 cm, women . 80 cm; ‘‘Glucose’’, elevated non-fasting glucose: $8.0 mmol/l or antidiabetic treatment (anatomic-therapeutical-chemical [ATC]
codes A10A, A10B); ‘‘HDL’’, decreased high-density lipoprotein cholesterol: men ,1.0 mmol/l, women ,1.3 mmol/l, or lipid-lowering treatment (ATC
C10AB, A10AD); ‘‘TG’’, elevated non-fasting triglycerides: $2.3 mmol/l or lipid-lowering treatment (ATC C10AB, A10AD); ‘‘BP’’, elevated blood
pressure: $130/85 mmHg or antihypertensive drug treatment. The size of a node is proportional to the number of individuals in the risk factor state
that the node represents. The inner circle of a node denotes individuals remaining in that risk factor state between baseline and follow-up, whereas
the outer circle of a node denotes individuals moving between risk factor states. The networks’ flow between baseline and follow-up is shown for the
39 most important links (13% of all 301 links), representing 84.5% of total flow. The weight and colour shade of a link represent the number of
individuals moving between the two states that the link connects.
doi:10.1371/journal.pone.0039461.g001
Visualized Risk Factor Clustering and Flow
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general population, and was also observed in previous population
studies [13,14] because in contrast to patient populations, there is
a large proportion of individuals without any MetS components
and a relatively low cardiovascular risk factor burden.
Obesity is becoming a global epidemic, with a continued
worldwide trend of increasing prevalences over the past four
decades [29]. Its public health impact stems from the notion that
obesity raises CVD risk through other risk factors including
dyslipidemia, hypertension, and hyperglycemia, and is therefore
the underlying risk factor in the pathogenesis of CVD [30]. For
example, the INTERHEART study examined more than 29,000
individuals in 52 countries to show that more than 90% of the risk
for acute myocardial infarction is predicted by nine traditional risk
factors including hypertension and central obesity [31]. In
a substudy of Latin American INTERHEART countries, central
obesity was the most important population-attributable risk factor
for acute myocardial infarction [32]. Using a different statistical
approach, a six-year follow-up of 506 men and 461 women from
the Baltimore Longitudinal Study on Aging identified higher
baseline abdominal obesity or triglycerides, and lower HDL
cholesterol as predictors of incident MetS [13]. Thus, despite
varying definitions of the MetS [19] and study samples, central
Table 1. Baseline and follow-up characteristics of the study population (N=3,187).
Characteristic Baseline Follow-up p-value
Age, years 50.0 (37.1, 61.6) 55.0 (42.2, 66.4) ,0.001
Sex (women), % 51.5 N.A.
Waist circumference, cm 89.0 (78.8, 98.5) 92.4 (82.5, 102.0) ,0.001
Diastolic blood pressure, mmHg 83.0 (76.0, 90.5) 81.0 (74.0, 88.0) ,0.001
Systolic blood pressure, mmHg 134.0 (121.0, 148.0) 131.0 (119.0, 144.0) ,0.001
High-density lipoprotein cholesterol (HDL-C), mmol/l 1.4 (1.2, 1.7) 1.1 (0.9, 1.4) ,0.001
Total cholesterol, mmol/l 5.7 (4.9, 6.5) 5.5 (4.7, 6.3) ,0.001
Low-density lipoprotein cholesterol, mmol/l 3.5 (2.8, 4.2) 3.5 (2.8, 4.2) 0.014
Triglyceride, mmol/l 1.5 (1.0, 2.3) 1.5 (1.0, 2.2) 0.895
Serum glucose, mmol/l 5.3 (4.9, 5.8) 5.2 (4.8, 5.7) ,0.001
Haemoglobin A1c, mmol/mol 34 (30, 39) 34 (30, 39) 0.447
Antidiabetic medication, % 5.2 8.4 ,0.001
Type 2 diabetes mellitus, % 10.5 12.8 ,0.001
Antihypertensive medication, % 22.6 36.0 ,0.001
Lipid-lowering medication, % 7.5 14.5 ,0.001
Cardiovascular disease, % 16.3 14.6 ,0.001
Metabolic syndrome, % 27.6 42.4 ,0.001
Elevated waist circumference, % 54.4 65.2 ,0.001
Elevated glucose, % 6.7 9.9 ,0.001
Decreased HDL-C, % 23.9 57.3 ,0.001
Elevated triglycerides, % 25.1 22.8 ,0.001
Elevated blood pressure, % 65.1 65.5 ,0.001
Data are presented as percentages or median (25
th and 75
th percentile).
*p-values based the x
2 test (categorical data) or T-test (continuous data).
doi:10.1371/journal.pone.0039461.t001
Table 2. Most dominant risk factor cluster at baseline (.5% of individuals).
Rank Risk factor cluster Baseline (%) Follow-up self-links (%) Follow-up out-flow (%)
1 Healthy 19.3 8.2 11.1
2 Obesity & BP 19.0 6.9 12.1
3 BP 15.4 4.7 10.8
4 Obesity, TG & BP 7.7 0.5 7.2
5 Obesity 6.3 1.5 4.8
6 Obesity, HDL, TG & BP 6.2 2.9 3.3
7 Obesity, HDL & BP 5.1 2.4 2.7
Follow-up self-links refers to the proportion of individuals who did not change their baseline risk factor profile at follow-up. Follow-up out-flow refers to the proportion
of individuals who did change their baseline risk factor profile at follow-up.
doi:10.1371/journal.pone.0039461.t002
Visualized Risk Factor Clustering and Flow
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the other MetS components [33].
The central role of hypertension in our MetS network analysis is
in line with a previous longitudinal investigation from the
Framingham Heart Study that found hypertension as the risk
factor most often associated with MetS diagnosis [14]. Similarly,
prior data from the National Health and Nutrition Examination
Survey (NHANES) showed that hypertension was the most
common MetS component in men and third most common in
women [34]. A recent Principal Components Analysis of MetS risk
Table 3. Risk factor flow for the 39 most important links.
Rank Risk factor cluster from baseline to follow-up
Change in number of
MetS components
Total flow
(%)
1 Healthy Healthy = 8.2
2 Obesity & BP Obesity & BP = 6.9
3 Obesity & BP Obesity, HDL & BP + 6.3
4B P B P = 4.6
5 Healthy HDL = 3.5
6 Obesity, HDL, TG, BP Obesity, HDL, TG & BP = 2.9
7 Obesity, TG & BP Obesity, HDL, TG & BP + 2.6
8 Obesity, HDL & BP Obesity, HDL & BP = 2.5
9 BP Obesity & BP + 2.2
10 Healthy BP = 2.1
11 Obesity & BP Obesity, HDL, TG & BP + 1.9
12 BP HDL & BP + 1.8
13 BP Obesity, HDL & BP + 1.8
14 BP Healthy = 1.7
15 Obesity Obesity & HDL + 1.7
16 Healthy Obesity = 1.6
17 Obesity, TG & BP Obesity, HDL & BP = 1.6
18 Obesity Obesity = 1.5
19 Obesity, TG & BP Obesity & BP 2 1.5
20 Obesity, HDL, TG & BP Obesity, HDL & BP 2 1.2
21 HDL HDL = 1.1
22 Healthy Obesity & HDL + 0.9
23 Obesity Obesity & BP + 0.9
24 BP HDL = 0.9
25 Obesity, HDL & BP Obesity, HDL, TG, & BP + 0.9
26 Obesity Obesity, HDL & BP + 0.9
27 Obesity, HDL, TG, BP & Glucose Obesity, HDL, TG, BP & Glucose = 0.8
28 Obesity & BP Obesity 2 0.8
29 Obesity & HDL Obesity & HDL = 0.7
30 HDL & BP HDL & BP = 0.7
31 Obesity, HDL, TG & BP Obesity, HDL, TG, BP & Glucose + 0.6
32 Obesity, BP & Glucose Obesity, HDL, BP & Glucose + 0.6
33 BP HDL, TG & BP + 0.6
34 Obesity & BP Obesity & HDL = 0.6
35 Obesity, TG, BP & Glucose Obesity, HDL, TG, BP & Glucose + 0.6
36 Healthy Obesity & BP + 0.5
37 Obesity & HDL Obesity, HDL & BP + 0.5
38 Healthy Obesity, HDL & BP + 0.5
39 Obesity, TG & BP Obesity, TG & BP = 0.5
These 39 most important links represent 13% of all 301 links covering 84.5% of the total flow.
‘‘Obesity’’, waist circumference: men .94 cm, women .80 cm;
‘‘Glucose’’, elevated glucose: $8.0 mmol/l or antidiabetic treatment;
‘‘HDL’’, decreased high-density lipoprotein cholesterol: men ,1.0 mmol/l, women ,1.3 mmol/l, or lipid-lowering treatment;
‘‘TG’’, elevated non-fasting triglycerides: $2.3 mmol/l or lipid-lowering treatment;
‘‘BP’’, elevated blood pressure: $130/85 mmHg or antihypertensive drug treatment.
doi:10.1371/journal.pone.0039461.t003
Visualized Risk Factor Clustering and Flow
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common MetS component [35]. But interestingly, the MetS
components with the highest prevalence prior to MetS de-
velopment, such as elevated blood pressure, are not necessarily
the strongest risk factors of incident MetS [13]. However, despite
the comparably high prevalence of hypertension within our study
region [36], these findings from different study populations and
geographic regions limit the potential impact of regional
differences on our revealed estimates.
Taken together, the predominant cardiovascular risk factor
cluster identified in the present MetS network analysis consists of
hypertension and central obesity. Our results suggest assessing
single cardiovascular risk factors as a simpler alternative to MetS
for CVD risk identification [10], especially in the general
population, before other MetS components appear clinically.
Similarly, the Framingham Heart Study identified a risk factor
combination of central obesity, hypertension, and hyperglycemia,
which more than doubled the risk of incident CVD and mortality
[14]. Analyzing trajectories of entering the MetS, central obesity
was also identified to confer the highest risk of incident MetS [14].
We showed that the contribution of the various cardiovascular
risk factors to the MetS individually and collectively is unbalanced
and therefore requires proper identification to provide adequate
treatment. To avoid obesity-initiated MetS and the downstream
clustering of additional cardiovascular risk factors like hyperten-
sion or dyslipidemia, lifestyle interventions that include increased
physical activity and dietary modifications offer an evidence-based
strategy for managing obesity [29], as well as prehypertension and
prediabetes [37]. Cardio-respiratory fitness has also been identified
as a key explanatory variable for the risks associated with obesity
and MetS. After inclusion of a variable reflecting cardio-
respiratory fitness into a statistical model predicting all-cause
and CVD mortality from MetS and obesity, the risk estimates were
no longer significant [38]. However, the fundamental challenge
remains how to intervene at the public health level to address the
obesity epidemic in the general population. The interventions
proven to be cost-effective and to prevent the transition to MetS
should be prioritized for implementation.
Strengths and limitations
Strengths of the present investigation include the high-quality
longitudinal data from a large-scale population-based epidemio-
logical cohort and its network-based visualization. Limitations may
arise from the use of non-fasting blood samples for the diagnosis of
ATP III defined MetS. But due to logistical concerns in a large-
scale population-based study like SHIP, it was practically
impossible to obtain such. However, the applied MetS definition,
based on non-fasting blood samples, was published in several
previous investigations related to MetS from our cohort
[10,20,21,39] and was suggested to be even the better surrogate
for the diagnosis of MetS, in particular for population-based
epidemiological studies like the present [40]. Furthermore, intra-
individual variation in the repeatedly assessed outcome measures
(including non-fasting triglycerides or glucose) may have caused
classification bias whose extent we were not able to evaluate using
network-based descriptive statistical analyses. However, given the
large sample size and the repeated one-point measurements of
MetS components, potential intra-individual variability is sup-
posed to cause misclassification into both directions.
Conclusions
Harvesting a network-based approach to visualize cardiovascu-
lar risk factor burden, expression, and change, we identified
hypertension and central obesity as the predominant MetS risk
factor cluster and low HDL concentrations as the most prominent
new onset risk factor. Interestingly, the identified subnetwork or
risk factor cluster has been shown to overlap within similar
pathophysiological processes finally leading to MetS, overt clinical
CVD, and mortality. However, prolonged efforts are needed to
identify high-risk individuals and to provide them with effective
evidence-based therapies. By revealing further insights into the
onset and progression of MetS risk factors, we have contributed to
the successful application of systems principles in epidemiology
[41], a new field tentatively named network medicine [42,43].
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